Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease small cell carcinoma
Comorbidity C0242379|lung cancer
Sentences 20
PubMedID- 25832826 Synchronous primary lung cancer presenting with small cell carcinoma and adenocarcinoma.
PubMedID- 21663995 However, by multi-variant analysis a ct scan would not be expected to reduce the risk of lung cancer mortality in patients with large/small cell carcinoma, although would be expected to reduce the risk of lung cancer death by 80% in cases of both adenocarcinoma and squamous cell carcinoma.
PubMedID- 23532607 lung cancer, predominantly non-small cell lung cancer (nsclc), is currently the most common cause of malignancy-related death in the world.
PubMedID- 25131571 lung cancer, including non-small cell lung cancer, remains prevalent in australia and has a very poor survival rate.
PubMedID- 22836614 A decreased intensity of survivin expression and fewer cells positive for survivin (66.7%) in sclc in comparison with other lung cancer types (98.0%) was detected.
PubMedID- 24404545 sclc mixed with non-small cell lung cancer.
PubMedID- 25600649 There remains a great need for effective therapies for lung cancer, the majority of which are non-small cell lung cancers (nsclc).
PubMedID- 23205280 Methods: lung function tests were performed to lung cancer patients with non-small cell lung cancer of stage i, ii, iii and iv (241 patients in total).
PubMedID- 23244181 It is classified into non-small cell lung cancer (nsclc) representing 70-80% of cases and small cell lung cancer (sclc) which has neuroendocrine properties with poor outcome.
PubMedID- 24094076 Results: eighteen of the 29 patients included in this study had lung cancer: 2 with small cell lung cancer and 16 with nonsmall cell lung cancer.
PubMedID- 25635972 lung cancer, which is of two types, small cell lung carcinoma and the non-small cell lung cancer, is the most common and fatal cancer.
PubMedID- 25383445 Particle therapy for clinically diagnosed stage i lung cancer: comparison with pathologically proven non-small cell lung cancer.
PubMedID- 22192801 Calcyclin (m/z= 10,094.7) was identified to be underexpressed in small cell lung cancers, as compared with non-small cell lung cancers and normal lung tissue.
PubMedID- 24280722 The objective of this study was to compare lung cancer survival in patients with non-small cell lung cancer with a diameter of 30 mm or less with clinical stage 1 disease who underwent lobectomy or sublobar resection.
PubMedID- 21595568 Context: nonsmall cell lung cancers with neuroendocrine differentiation (nsclc-nd) may demonstrate biologic behavior intermediate between nsclc and small cell lung cancer (sclc) with impact on prognosis.
PubMedID- 22696682 These results show that cdk5 and its activator p35 are expressed in human lung cancer cell lines of non–small cell lung cancer (nsclcs) and sclcs, at both the mrna and protein levels.
PubMedID- 25593718 Dvt developed more frequently in lung cancer (42%) with small cell carcinoma being the most common pathologic finding (42.9%) in those with lung cancer (p = 0.0001).
PubMedID- 24518087 One hundred thirty-seven proteins were differentially expressed in sclc compared with non-small-cell lung cancer and immortalized normal bronchial epithelial cells.
PubMedID- 25640394 Materials and methods: retrospectively, 130 patients were selected at the time of diagnosis oflung cancer (100 with nsclc and 30 with sclc), before the initialization of any chemo-radiotherapy.
PubMedID- 25332036 Objective: to investigate opportunities to reduce lung cancer mortality after diagnosis of localised non-small cell lung cancer (nsclc) in new south wales through surgical resection.

Page: 1